Zevra Therapeutics, Inc. (ZVRA) P/E Ratio History
UndervaluedTrading at 10.0x vs 5Y avg 48.9x · 50th percentile · Below historical baseline · Data 2022–2026
Loading P/E history...
P/E Ratio Analysis
As of June 28, 2026, Zevra Therapeutics, Inc. (ZVRA) trades at a price-to-earnings ratio of 10.0x, with a stock price of $13.52 and trailing twelve-month earnings per share of $2.06.
The current P/E is 80% below its 5-year average of 48.9x. Over the past five years, ZVRA's P/E has ranged from a low of 4.3x to a high of 169.9x, placing the current valuation at the 50th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, ZVRA trades at a 56% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, ZVRA trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ZVRA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ZVRA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ZVRA P/E vs Peers
Commercial Rare Disease Biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 11.1 | -Best | +68% | |
| $7B | 10.9Lowest | -Best | +264%Best | |
| $11B | 54.4 | -Best | +128% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ZVRA Historical P/E Data (2022–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $9.32 | $2.15 | 4.3x | -91% |
| FY2025 Q4 | Dec 31 2025 | $8.96 | $1.49 | 6.0x | -88% |
| FY2025 Q3 | - | $9.51 | $0.62 | 15.3x | -69% |
| FY2022 Q1 | - | $5.03 | $0.03 | 169.9x | +248% |
Average P/E for displayed period: 48.9x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ZVRA — Frequently Asked Questions
Quick answers to the most common questions about buying ZVRA stock.
What is ZVRA's P/E ratio?
Zevra Therapeutics, Inc. (ZVRA) trailing twelve-month P/E ratio is 10.0x, based on TTM diluted EPS of $2.06. The 5-year average P/E is 48.9x and the historical range spans 4.3x to 169.9x.
Is ZVRA stock overvalued or undervalued?
ZVRA trades at 10.0x P/E, below its 5-year average of 48.9x. At the 50th percentile of its historical range (4.3x–169.9x), the stock is priced at a discount to its own history.
Is ZVRA stock expensive?
No, ZVRA is not expensive on a historical basis. The current P/E of 10.0x is below the 5-year average of 48.9x and sits at the 50th percentile of its valuation range.
What is ZVRA's historical P/E range?
Over the past 5 years, ZVRA's P/E ratio has ranged from 4.3x to 169.9x, with a median of 15.3x and an average of 48.9x. The current P/E of 10.0x places the stock at the 50th percentile of this range. Full historical data spans 2022–2026.
How does ZVRA's P/E compare to the S&P 500?
ZVRA trades at 10.0x P/E versus the S&P 500 median of 25.3x. The 60% discount to the market suggests lower growth expectations or perceived higher risk.
How does ZVRA's valuation compare to Healthcare peers?
Zevra Therapeutics, Inc. P/E of 10.0x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ZVRA's PEG ratio?
ZVRA PEG ratio is N/A, based on a P/E of 10.0x and EPS growth of 159.2%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ZVRA's earnings yield?
ZVRA earnings yield is 9.99%, the inverse of its 10.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.